Arcus Biosciences Inc (RCUS) has released an update to notify the public and investors about its officers.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
On January 29, 2024, Dr. Jaen and Ms. Jarrett resigned from the Board, and Johanna Mercier was subsequently appointed as a Class II director. Their resignations did not stem from any disagreements with the Company’s operations or policies. Ms. Mercier, the Chief Commercial Officer of Gilead, was appointed in accordance with the rights established by the A&R Investor Rights Agreement and will serve without compensation. The Company plans to provide her with a standard indemnification agreement.
For further insights into RCUS corporate activity, check out TipRanks’ Insiders Trading Activity page.
For a comprehensive understanding of the announcement, you can read the full document here.